On September 27, 2023 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, reported that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023) to be held in San Diego from November 1-5, 2023 (Press release, Antengene, SEP 27, 2023, View Source [SID1234635472]). As the world’s largest and most anticipated gathering in the field of immuno-oncology, the SITC (Free SITC Whitepaper) Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations feature five Antengene’s clinical and preclinical programs, including two clinical programs, the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101; two preclinical programs, the LILRB4 antagonist antibody ATG-034 and the GPRC5D/CD3 T-cell engager ATG-021; as well as the proprietary novel AnTenGager platform.
Details of those poster presentations
ATG-031(anti-CD24 monoclonal antibody)
Title: The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignancies
Abstract: 1337
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023
ATG-101(PD-L1/4-1BB bispecific antibody)
Title: Single-cell RNA sequencing reveals the positive feedback activation loop between T and dendritic cells induced by PD-L1x4-1BB bispecific antibody
Abstract: 1112
Date: November 4, 2023
Time: 9:00 AM – 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023
ATG-034 (LILRB4 antagonist antibody)
Title: Antibody targeting a specific epitope of LILRB4 induces potent ADCC/ADCP effect against leukemia cells
Abstract: 1391
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023
ATG-021 (GPRC5D/CD3 T-cell engager)
Title: ATG-021, a novel 2+1 CD3-based T-cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release
Abstract: 1191
Date: November 3, 2023
Time: 9:00 AM – 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023
AnTenGager Platform
Title: A novel "2+1" bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
Abstract: 1190
Date: November 4, 2023
Time: 9:00 AM – 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023